Cancer test clearance
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson/Veridex gains 510(k) clearance for use of its CellSearch test system as an aid in monitoring metastatic colorectal cancer. The system, which counts circulating tumor cells, is already cleared to help monitor metastatic beast cancer. The CellSearch test reagents are supplied by Immunicon, but that company is seeking to terminate the exclusive marketing agreement it has with Veridex (1"The Gray Sheet" June 11, 2007, p. 10)